Phase 2Withdrawn
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy
- Sponsor
- Galectin Therapeutics Inc. (Industry)
- Conditions
- Colorectal Cancer
- Interventions
- GM-CT-01; 5-Fluorouracil, Leukovorin, bevacizumab
- Ages
- adults, older adults
- Registry
- NCT00388700
Full record on ClinicalTrials.gov
From the registry
The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in patients unable to tolerate intensive chemotherapy.
Primary outcomes
- Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.
History
Last registry update
Primary completion
Registered
Started